Articles

Moderna and Generation Bio have announced a strategic collaboration to develop non-viral genetic medicines. 

Moderna and Generation Bio Announce Strategic Collaboration

Curia is collaborating with Corning to advance biopharmaceutical continuous-flow development and manufacturing programs.

Curia and Corning Collaborate to Advance Biopharmaceutical Continuous-Flow Development

 Washington Editor, jillwechsler7@gmail.com.

A new Interagency Working Group for Bayh-Dole will review the government’s authority to revoke licenses for medical products.

Feds to Review March-In Authority on Drug Patents

The recent document will guide the use of DHT-derived data in regulatory decision-making for drugs and biological products.

Digital Health Technologies Document Outlines Framework for FDA

Cheryl Barton is director of PharmaVision, 

TreeFrog Therapeutics is leaping ahead in cell therapies through 
resources such as new technologies and investor partnerships.


Frontrunners in the Latest Stem Cell Technology

Feliza Mirasol is the science editor for 

Under a new partnership, Invitae and Deerfield Management will harness genetic and clinical testing data from patients to discover potential novel therapeutics for treating rare diseases.

Invitae and Deerfield Management Team Up on Novel Therapeutics for Rare Diseases

Susan Haigney is managing editor of BioPharm International, susan.haigney@ubm.com.

In addition to a new interim president, the company is opening new microbial capacity at its San Antonio facility and has plans to construct a commercial-scale facility in Manhattan, Kan.

Scorpius BioManufacturing Announces New Microbial Capacity and New Interim President

The combined solutions are currently available on the market.

TrakCel and Lonza Reach Integration Milestone to Combine Cell and Gene Therapy Manufacturing, Orchestration Solutions 

The services are based on the company’s PurePrep EasyClean (PEC) orthogonal peptide purification technology.

PurePep EasyClean Services Set to Accelerate Development and Manufacturing of Peptide-based Drugs 

The decision was based on results from the PROpel Phase III trial.

All News